If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
Sanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.
The manufacturer has moved to a four day working week and says it is now rebuilding market share following a challenging ...
Zacks.com on MSN9h
Pharma Stock Roundup: PFE, LLY, NVO, LLY and AZN's Q4 Earnings UpdateThis week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...
This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, AstraZeneca AZN and AbbVie announced their fourth-qua ...
Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, ...
The company plans to allocate a record amount to capital expenditures to build artificial-intelligence infrastructure.
AstraZeneca PLC (AZN) reports a robust 21% revenue increase for 2024, while navigating market challenges and strategic ...
Amazon faced ~900 Mn FX headwind in 4Q’24 which was ~700 mn higher than assumed. For the third consecutive quarter, AWS grew ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback